Is Ejaculation Preservation TURis the Natural Evolution of the "Gold Standard".

Benign Prostatic Hyperplasia Clinical Trial

Official title:

Ejaculatory Preserving Transurethral Resection of the Prostate.

Clinical Trial Details — Status: Completed

Administrative data

• NCT number: NCT06263049
• Other study ID #: ejaculation post TURP
• Status: Completed
• Phase: N/A
• Start date: May 1, 2023
• Est. completion date: February 1, 2024

Study information

• Verified date: January 2024
• Source: Ain Shams University
• Contact: n/a
• Is FDA regulated: No
• Study type: Interventional

Clinical Trial Summary

evaluation of the impact of apical urethral mucosa sparring with the urethra around the verumontanum on the ejaculatory function and early postoperative urinary incontinence

Description:

Benign Prostatic Hyperplasia (BPH) is a common disease in elderly men and transurethral resection of the prostate (TURP) is still the gold standard for the treatment of BPH However, postoperative urinary incontinence (UI) and retrograde ejaculation are of the common complications and its incidence is nearly 2% of UI UI brings great suffering to patients and its unpredictability and uncertainty in the recovery period cause significant pressure to surgeons. External urethral sphincter damage is the main reason for UI after prostatectomy. The treatment of postoperative UI and post operative retrograde ejaculation has also become an important issue for many years. Along with the progress of technology, there have been various methods of transurethral resection of the prostate but no method has been found to adequately avoid the occurrence of UI and retrograde ejaculation

Recruitment information / eligibility

• Status: Completed
• Enrollment: 106
• Est. completion date: February 1, 2024
• Est. primary completion date: January 1, 2024
• Accepts healthy volunteers: Accepts Healthy Volunteers
• Gender: Male
• Age group: 40 Years and older

Eligibility

Our inclusion criteria were preidentified to those who complained of voiding lower urinary tract symptoms (LUTS) and scheduled for TURP with prostate size less than 100 gm. This included patients with refractory retention, recurrent gross hematuria of prostatic origin, non-compliance to medical treatment, recurrent infection, and patients with bladder calculi secondary to obstruction. Exclusion criteria were: patients with neurogenic bladder, detrusor hypo-contractility, Diabetes more than 10 years, urethral stricture, or previous prostatic surgeries.

Related Conditions & MeSH terms

• Benign Prostatic Hyperplasia
• Hyperplasia
• Prostatic Hyperplasia

Intervention

Procedure:
• transurethral resection of prostate
resection of prostate by using bipolar cautarization

Locations

Country	Name	City	State
Egypt	Ain shams university	Cairo

Sponsors (1)

Lead Sponsor	Collaborator
Ain Shams University

Country where clinical trial is conducted

Egypt, 

References & Publications (1)

Liang JQ, Ma WT, Lu BW, Dai L, Zhao YM, Zhang JD, Tian B, Liu QL. Clinical Study on the Application of Preserved Urethral Mucosa at the Prostatic Apex in Transurethral Plasmakinetic Resection of the Prostate. Front Surg. 2022 Jun 17;9:922479. doi: 10.3389 — View Citation

Outcome

Type	Measure	Description	Time frame	Safety issue
Primary	post operative antegrade ejaculation	the ability of the person to ejaculate post TURP procedure	within 1 month post operative
Secondary	post operative urine continence	early postoperative urine continence	within 1 month post operative